Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
| ▸ | CCR6 | P51684 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13956786 | 0.78 | EPHX1 (0.62) | MAPTALDH1A1ALOX12CCR6GAA | |
| SCHEMBL6814399 | 0.76 | MAPT (0.55) | MAPTALDH1A1GAANPC1RAB9A | |
| SCHEMBL22025463 | 0.74 | NPC1 (0.63) | MAPTALDH1A1GAANPC1RAB9A | |
| SCHEMBL13956778 | 0.74 | MEN1 (0.67) | MAPTALDH1A1ALOX12MEN1KMT2A | |
| SCHEMBL4364669 | 0.73 | NPC1 (0.56) | MAPTALDH1A1ALOX12CCR6GAA | |
| SCHEMBL4365512 | 0.73 | NPC1 (0.56) | MAPTALDH1A1ALOX12CCR6GAA | |
| SCHEMBL4334835 | 0.73 | KMT2A (0.53) | MAPTALDH1A1GAAKMT2ANPC1 | |
| SCHEMBL6814411 | 0.73 | MAPT (0.60) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL9900412 | 0.73 | MAPT (0.69) | MAPTALDH1A1ALOX12CCR6GAA | |
| SCHEMBL4375215 | 0.73 | NPC1 (0.53) | MAPTALDH1A1ALOX12CCR6GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143419-B2 | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA N. V. (BE) | 2012-03-27 | — | — | US | disclosed |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | CHRNA1, CHRNA5, CHRNA3 | MAPT 1731/4885ALDH1A1 1480/4885ALOX12 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.